GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Enter: “Your Cancer Is Our Challenge,” a new initiative that GSK unveiled Tuesday with an aim of raising awareness of and ...

Cash and cash equivalents amounted to EUR 550.9 million at the end of September 2024, increasing from EUR 402.5 million at the end of 2023. The ...

GlaxoSmithKline is under pressure from shareholders ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...

GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024 GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

ii This approval underscores GSK's commitment to help drive progress for people living with complex blood cancers.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...